HOME >> BIOLOGY >> NEWS
Latest data shows MabThera provides significant, sustained relief from symptoms of RA

Barcelona, Spain. New data presented at the EULAR meeting (European League Against Rheumatism) demonstrate that MabThera's (rituximab) effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis (RA) is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission1. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.

Commenting on the findings, Professor Keystone, Rheumatology Department at the University of Toronto, Canada, said: "As physicians gain experience with MabThera and the long-term efficacy and safety data are collected, we are able to make treatment decisions with confidence for the ultimate benefit of our patients."

Results following subsequent courses of therapy

A total of 1053 RA patients was treated with MabThera with almost 70% of patients followed up for more than two years and 11% for more than three years. The study was conducted in patients who had an inadequate response to treatment with either tumour necrosis factor (TNF) inhibitors or disease-modifying anti-rheumatic drugs (DMARDs), both of which are commonly used classes of RA drugs. All study patients received multiple courses of MabThera (2 x1000mg infusion, 2 weeks apart) based on disease activity.

The data showed that after three courses of MabThera in patients who had an inadequate response to TNF inhibitors:

  • The number of patients achieving the hard-to-reach goal of a 70% improvement in disease signs and symptoms (ACR70 response2) almost tripled from 11% to 25%

  • The number of patients achieving remission improved from 6% to 12%

Equally, in patients with an inadequate response or intolerance to DMARDs, the remission rate increased almost threefold from 5% to 14% confirming the benefit of providing subsequen
'"/>

Contact: Lynn Huynh
lynn_huynh@uk.cohnwolfe.com
44-207-331-5332
Cohn & Wolfe, London
13-Jun-2007


Page: 1 2

Related biology news :

1. Latest strategies for moving research toward a cure for diabetes explored at global scientific forum
2. Latest plant health research to be presented in San Diego
3. Latest advances in DNA sequencing highlighted at DOE Joint Genome Institute User Meeting
4. Latest buzz: Marijuana may slow progression of Alzheimers disease
5. Latest enhancements to the free Access Grid Toolkit are now available for download
6. Slow-frozen people? Latest research supports possibility of cryopreservation
7. Latest plant disease research to be presented in Quebec City
8. Latest study: Scientists say no evidence exists that therapod dinosaurs evolved into birds
9. Latest gene therapy research to be presented in St. Louis, June 1-5, 2005
10. Latest census finds more American pika populations disappear as climate warms
11. Latest buzz in research: Intoxicated honey bees may clue scientists into drunken human behavior

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... 2017 , ... Arrowhead Publishers is pleased to announce the ... San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, biotech, device ... the treatment of various types of pain. There are also extended networking opportunities, ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... mass flow controllers based on capillary thermal mass flow technology provide exponentially more ... control applications. Over 80% of all industrial processes—such as those involving chemical ...
(Date:4/27/2017)... Washington, USA (PRWEB) , ... April 27, 2017 ... ... for optics and photonics , joined other scientists, researchers, engineers, and industry professionals ... measures to strengthen America's ability to compete in the world photonics industry. , ...
(Date:4/27/2017)... 2017  Pendant Biosciences, Inc. (formerly Nanoferix, Inc.), a ... drug delivery technologies, today announced that it has been ... Toronto . Shawn Glinter ... noted, "We are excited to become part of the ... are honored to be the first Tennessee ...
Breaking Biology Technology:
Cached News: